THERAPEUTIC GUIDANCE AND/OR MONITORING THERAPY FOR TREATING SHOCK Russian patent published in 2025 - IPC G01N33/68 G16H50/30 A61K38/22 A61K39/395 A61K45/06 A61P9/00 A61P43/00 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to emergency medicine. Disclosed are methods for predicting and diagnosing refractory shock in a patient, including determining the level of DPP3 in a patient's sample, where, if the DPP3 level exceeds value from 20 to 200 ng/ml, it is predicted or determined that the said patient falls into a state of refractory shock. Methods for predicting the risk of an adverse event and an outcome in a patient developing refractory shock are disclosed. What is presented is the use of a vasopressor in the therapy of shock in a patient. Disclosed is the use of a DPP3 activity inhibitor in the therapy of shock in a patient, where the DPP3 activity inhibitor is an anti-DPP3 antibody, or an anti-DPP3 antibody fragment, or a non-Ig anti-DPP3 framework. Disclosed are methods of treating shock in a patient, involving administering a vasopressor or DPP3 activity inhibitor to said patient.

EFFECT: presented group of inventions provides effective methods of diagnosing, predicting refractory shock, as well as treating shock in a patient by determining the DPP3 level in a biological fluid sample of said patient.

20 cl, 16 dwg, 9 tbl, 11 ex